Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Salary Range:CHF102,200.00 - CHF189,800.00 Job Description SummaryLocation: Basel or Cambridge Onsite Relocation is offered for this role. #LI-Onsite The Oncology Data Science team in Biomedical Research at Novartis works at the intersection of oncology drug discovery,
Salary Range:CHF78,400.00 - CHF145,600.00 Job Description SummaryLocation: Basel or Cambridge Onsite Relocation is offered for this role. #LI-Onsite The Oncology Data Science team in Biomedical Research at Novartis works at the intersection of oncology drug discovery,
At Roche you can show up as yourself, embraced for the unique qualities you bring. Our culture encourages personal expression, open dialogue, and genuine connections, where you are valued, accepted and respected for who you are,
At Roche you can show up as yourself, embraced for the unique qualities you bring. Our culture encourages personal expression, open dialogue, and genuine connections, where you are valued, accepted and respected for who you are,
Professorship in Distributed Data and Knowledge Engineering (open rank) The University of Basel invites applications for a Professorship in Distributed Data and Knowledge Engineering to join the Department of Mathematics and Computer Science (DMI). This position strengthens
Professorship in Distributed Data and Knowledge Engineering (open rank) The University of Basel invites applications for a Professorship in Distributed Data and Knowledge Engineering to join the Department of Mathematics and Computer Science (DMI). This position strengthens
Job description Location: Basel, Zurich, Geneva Work Pattern Percentage: 80-100% Help our clients navigate the future with confidence and embrace decision making with clear data-driven choices Deloitte AI & Data helps clients unlock the power of
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS‑addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Position Title PhD position in theoretical and computational chemistry/biophysics in the group of Markus Meuwly in the Department of Chemistry at the University of Basel, Switzerland. Responsibilities and Scope The main theme of our research is